JP3848164B2 - 軟部組織修復用の前脂肪細胞からなるバイオマテリアル - Google Patents

軟部組織修復用の前脂肪細胞からなるバイオマテリアル Download PDF

Info

Publication number: JP3848164B2
Authority: JP; Japan
Prior art keywords: hyaluronic acid; preadipocytes; cells; ester; soft tissue
Prior art date: 2000-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2001579862A

Other languages

English (en)

Japanese (ja)

Other versions

JP2003531684A5 (fr

JP2003531684A (ja

Inventor

デニス・フォン・ハイムブルク

アレッサンドラ・パヴェシオ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Anika Therapeutics SRL

Original Assignee

Fidia Advanced Biopolymers SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-03

Filing date

2001-05-03

Publication date

2006-11-22

2001-05-03 Application filed by Fidia Advanced Biopolymers SRL filed Critical Fidia Advanced Biopolymers SRL

2003-10-28 Publication of JP2003531684A publication Critical patent/JP2003531684A/ja

2005-12-22 Publication of JP2003531684A5 publication Critical patent/JP2003531684A5/ja

2006-11-22 Application granted granted Critical

2006-11-22 Publication of JP3848164B2 publication Critical patent/JP3848164B2/ja

2021-05-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004872 soft tissue Anatomy 0.000 title claims abstract description 22
210000000229 preadipocyte Anatomy 0.000 title claims description 64
239000012620 biological material Substances 0.000 title claims description 12
230000017423 tissue regeneration Effects 0.000 title description 3
229920002674 hyaluronan Polymers 0.000 claims abstract description 77
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 72
229960003160 hyaluronic acid Drugs 0.000 claims abstract description 62
239000000463 material Substances 0.000 claims abstract description 39
238000002360 preparation method Methods 0.000 claims abstract description 22
150000001408 amides Chemical class 0.000 claims abstract description 15
150000002148 esters Chemical class 0.000 claims abstract description 12
-1 benzyl ester Chemical class 0.000 claims description 35
210000002901 mesenchymal stem cell Anatomy 0.000 claims description 16
210000002889 endothelial cell Anatomy 0.000 claims description 14
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical group CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 claims description 10
230000007547 defect Effects 0.000 claims description 9
238000011049 filling Methods 0.000 claims description 6
210000005260 human cell Anatomy 0.000 claims description 6
230000037303 wrinkles Effects 0.000 claims description 2
230000000451 tissue damage Effects 0.000 claims 2
231100000827 tissue damage Toxicity 0.000 claims 2
239000002243 precursor Substances 0.000 abstract description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 4
238000002278 reconstructive surgery Methods 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 54
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
210000001789 adipocyte Anatomy 0.000 description 38
239000000243 solution Substances 0.000 description 36
238000006243 chemical reaction Methods 0.000 description 35
239000000515 collagen sponge Substances 0.000 description 28
210000001519 tissue Anatomy 0.000 description 28
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
238000001727 in vivo Methods 0.000 description 22
239000002244 precipitate Substances 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
210000004204 blood vessel Anatomy 0.000 description 20
238000003756 stirring Methods 0.000 description 20
238000004519 manufacturing process Methods 0.000 description 19
239000000047 product Substances 0.000 description 17
238000000034 method Methods 0.000 description 16
230000035515 penetration Effects 0.000 description 15
210000000577 adipose tissue Anatomy 0.000 description 14
230000004069 differentiation Effects 0.000 description 14
102000008186 Collagen Human genes 0.000 description 13
108010035532 Collagen Proteins 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
229920001436 collagen Polymers 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
229940099552 hyaluronan Drugs 0.000 description 12
239000011148 porous material Substances 0.000 description 12
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 11
238000002054 transplantation Methods 0.000 description 11
238000004566 IR spectroscopy Methods 0.000 description 10
241000699660 Mus musculus Species 0.000 description 10
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 10
238000011580 nude mouse model Methods 0.000 description 10
238000000870 ultraviolet spectroscopy Methods 0.000 description 10
230000033115 angiogenesis Effects 0.000 description 9
239000000835 fiber Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
230000009435 amidation Effects 0.000 description 8
238000007112 amidation reaction Methods 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 7
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
210000002744 extracellular matrix Anatomy 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
210000000130 stem cell Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 5
230000006181 N-acylation Effects 0.000 description 5
JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
238000004737 colorimetric analysis Methods 0.000 description 5
210000002808 connective tissue Anatomy 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
239000003480 eluent Substances 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
239000013642 negative control Substances 0.000 description 5
239000011347 resin Substances 0.000 description 5
229920005989 resin Polymers 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002513 implantation Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000010186 staining Methods 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 4
238000009827 uniform distribution Methods 0.000 description 4
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
101000803403 Homo sapiens Vimentin Proteins 0.000 description 3
229920002385 Sodium hyaluronate Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
229930016911 cinnamic acid Natural products 0.000 description 3
235000013985 cinnamic acid Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
238000002316 cosmetic surgery Methods 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
102000057393 human VIM Human genes 0.000 description 3
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
150000004804 polysaccharides Chemical class 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
229940010747 sodium hyaluronate Drugs 0.000 description 3
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000003934 vacuole Anatomy 0.000 description 3
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000003381 deacetylation reaction Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000004745 nonwoven fabric Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
GNYWBJRDQHPSJL-UHFFFAOYSA-N 6-acetyl-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid Chemical compound CC(=O)C1(O)C=CC=CC1C(O)=O GNYWBJRDQHPSJL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HSEMFIZWXHQJAE-UHFFFAOYSA-N Amide-Hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(N)=O HSEMFIZWXHQJAE-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
241000272814 Anser sp. Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229920000049 Carbon (fiber) Polymers 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
229920001284 acidic polysaccharide Polymers 0.000 description 1
150000004805 acidic polysaccharides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000011759 adipose tissue development Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
BWWWINRCJYEXTH-UHFFFAOYSA-N aminoazanium sulfate hydrate Chemical compound S(=O)(=O)([O-])[O-].O.[NH3+]N.[NH3+]N BWWWINRCJYEXTH-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000007664 blowing Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000004917 carbon fiber Substances 0.000 description 1
238000009960 carding Methods 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
238000004042 decolorization Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000032459 dedifferentiation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
229960000305 enflurane Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000004021 humic acid Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000013048 microbiological method Methods 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
201000002266 mite infestation Diseases 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
210000000299 nuclear matrix Anatomy 0.000 description 1
IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
210000001991 scapula Anatomy 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
125000002348 vinylic group Chemical group 0.000 description 1
238000005406 washing Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3808—Endothelial cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oral & Maxillofacial Surgery (AREA)
Medicinal Chemistry (AREA)
Transplantation (AREA)
Zoology (AREA)
Botany (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Developmental Biology & Embryology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Materials For Medical Uses (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

JP2001579862A 2000-05-03 2001-05-03 軟部組織修復用の前脂肪細胞からなるバイオマテリアル Expired - Fee Related JP3848164B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20198400P	2000-05-03	2000-05-03
US60/201,984		2000-05-03
PCT/EP2001/005087 WO2001082991A2 (fr)	2000-05-03	2001-05-03	Biomateriaux composes de cellules preadipocytes conçus pour reparer des tissus mous

Publications (3)

Publication Number	Publication Date
JP2003531684A JP2003531684A (ja)	2003-10-28
JP2003531684A5 JP2003531684A5 (fr)	2005-12-22
JP3848164B2 true JP3848164B2 (ja)	2006-11-22

Family

ID=22748090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001579862A Expired - Fee Related JP3848164B2 (ja)	2000-05-03	2001-05-03	軟部組織修復用の前脂肪細胞からなるバイオマテリアル

Country Status (9)

Country	Link
US (1)	US20040037810A1 (fr)
EP (1)	EP1280562B1 (fr)
JP (1)	JP3848164B2 (fr)
AT (1)	ATE283714T1 (fr)
AU (2)	AU2001273992B2 (fr)
CA (1)	CA2407925C (fr)
DE (1)	DE60107560T2 (fr)
ES (1)	ES2233650T3 (fr)
WO (1)	WO2001082991A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2850282B1 (fr)	2003-01-27	2007-04-06	Jerome Asius	Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation
EP2450433A3 (fr)	2003-10-08	2012-08-08	Vet-Stem Inc	Procédés de préparation et d'utilisation de compositions de cellules souches et kits le comportant
EP1793874B1 (fr) *	2004-06-30	2012-12-19	The Board Of Trustees Of The University Of Illinois	Dispostif pour tissu souple comprenant des cellules souches mésenchymales adultes
ITPD20040265A1 (it) *	2004-10-27	2005-01-27	Fidia Advanced Biopolymers Srl	Innesti vascolari costituiti da derivati dell'acido ialuronico in forma tubulare
JP2008526916A (ja) *	2005-01-19	2008-07-24	フィディアアドバンスドバイオポリマーズソシエタアレスポンサビリタリミタータ	Ｓｃｉおよびｐｎｔ再生のためのヒアルロン酸誘導体および神経幹細胞
KR101457231B1 (ko) *	2006-04-19	2014-11-12	고쿠리츠 다이가쿠 호우징 나고야 다이가쿠	치주 연조직 재생용 조성물 및 그 제조 방법
TW200817019A (en) *	2006-07-10	2008-04-16	Univ Columbia	De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells
RU2709780C2 (ru)	2007-09-19	2019-12-20	Плуристем Лтд.	Адгезивные клетки жировой ткани или плаценты и их использование в лечебных целях
WO2009056804A2 (fr) *	2007-10-29	2009-05-07	Orthomimetics Ltd	Biomatériau composite élastique
EP2740498A3 (fr) *	2008-07-02	2014-09-10	Allergan, Inc.	Compositions et procédés de remplissage et de régénération de tissus
WO2013010045A1 (fr)	2011-07-12	2013-01-17	Biotime Inc.	Nouveaux procédés et formulations pour thérapie cellulaire orthopédique
EP3355948A4 (fr) *	2015-10-02	2019-06-12	Robert Diluccio	Composition pour l'augmentation des tissus mous procurant une protection contre l'infection
EP3638266A1 (fr) *	2017-06-12	2020-04-22	BioTime, Inc.	Implants, procédés de fabrication d'implants et méthodes de traitement de défauts de lipoatrophie avec ceux-ci
EP3787702B1 (fr)	2018-05-03	2024-08-07	CollPlant Ltd.	Produits de comblement cutanés et leurs applications
KR102482470B1 (ko) *	2019-04-11	2022-12-28	연세대학교 산학협력단	혈관 신생 촉진용 조성물 및 이의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4851346A (en) *	1984-04-19	1989-07-25	Miles Inc.	Chemically defined growth medium
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5783408A (en) *	1995-06-07	1998-07-21	Hamilton; Bradford S.	Method for screening potential anti-obesity agents
US6482231B1 (en) *	1995-11-20	2002-11-19	Giovanni Abatangelo	Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
IT1282207B1 (it) *	1995-11-20	1998-03-16	Fidia Advanced Biopolymers Srl	Sistemi di coltura di cellule staminali di midollo osseo umano in matrici tridimensionali costituiti da esteri dell'acido ialuronico
EP0907721A1 (fr) *	1996-05-28	1999-04-14	Brown University Research Foundation	Charpentes biodegradables a base de hyaluronan destinees a la reparation tissulaire
IT1293484B1 (it) *	1997-06-11	1999-03-01	Fidia Advanced Biopolymers Srl	Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile
IT1296689B1 (it) *	1997-11-06	1999-07-14	Fidia Advanced Biopolymers Srl	Derivati esterei dell'acido ialuronico aventi proprieta viscoelastiche e loro uso in campo biomedico-sanitario
ITPD980149A1 (it) *	1998-06-17	1999-12-17	Fidia Advanced Biopolymers Srl	Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la
ITPD980169A1 (it) *	1998-07-06	2000-01-06	Fidia Advanced Biopolymers Srl	Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US6328765B1 (en) *	1998-12-03	2001-12-11	Gore Enterprise Holdings, Inc.	Methods and articles for regenerating living tissue
IT1302534B1 (it) *	1998-12-21	2000-09-05	Fidia Advanced Biopolymers Srl	Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per

2001
- 2001-05-03 DE DE60107560T patent/DE60107560T2/de not_active Expired - Lifetime
- 2001-05-03 AU AU2001273992A patent/AU2001273992B2/en not_active Ceased
- 2001-05-03 ES ES01940405T patent/ES2233650T3/es not_active Expired - Lifetime
- 2001-05-03 AU AU7399201A patent/AU7399201A/xx active Pending
- 2001-05-03 JP JP2001579862A patent/JP3848164B2/ja not_active Expired - Fee Related
- 2001-05-03 US US10/275,085 patent/US20040037810A1/en not_active Abandoned
- 2001-05-03 AT AT01940405T patent/ATE283714T1/de not_active IP Right Cessation
- 2001-05-03 WO PCT/EP2001/005087 patent/WO2001082991A2/fr active IP Right Grant
- 2001-05-03 EP EP01940405A patent/EP1280562B1/fr not_active Expired - Lifetime
- 2001-05-03 CA CA002407925A patent/CA2407925C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60107560T2 (de)	2006-01-05
ES2233650T3 (es)	2005-06-16
US20040037810A1 (en)	2004-02-26
EP1280562B1 (fr)	2004-12-01
JP2003531684A (ja)	2003-10-28
EP1280562A2 (fr)	2003-02-05
DE60107560D1 (de)	2005-01-05
ATE283714T1 (de)	2004-12-15
AU7399201A (en)	2001-11-12
WO2001082991A2 (fr)	2001-11-08
AU2001273992B2 (en)	2005-08-04
CA2407925A1 (fr)	2001-11-08
WO2001082991A3 (fr)	2002-04-25
CA2407925C (fr)	2008-12-16

Publication	Publication Date	Title
Wang et al.	2018	Fabrication of nanofibrous microcarriers mimicking extracellular matrix for functional microtissue formation and cartilage regeneration
Zhang et al.	2021	Photo-crosslinkable amniotic membrane hydrogel for skin defect healing
JP3848164B2 (ja)	2006-11-22	軟部組織修復用の前脂肪細胞からなるバイオマテリアル
KR101650957B1 (ko)	2016-08-24	세포외 기질 조성물
RU2631488C2 (ru)	2017-09-22	Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях
DE69924006T2 (de)	2006-01-26	Injizierbares hyaluronsäurederivat mit pharmazeutika/zellen
Lin et al.	2015	In vitro and in vivo evaluation of the developed PLGA/HAp/Zein scaffolds for bone-cartilage interface regeneration
Li et al.	2016	Application potential of bone marrow mesenchymal stem cell (BMSCs) based tissue-engineering for spinal cord defect repair in rat fetuses with spina bifida aperta
EP1423082A4 (fr)	2006-02-08	Matrices a base de proteines de plasma et procedes de fabrication
Xie et al.	2016	Adult stem cells seeded on electrospinning silk fibroin nanofiberous scaffold enhance wound repair and regeneration
AU2001273992A1 (en)	2002-01-31	Biomaterials comprised of preadipocyte cells for soft tissue repair
EP3746049A1 (fr)	2020-12-09	Vésicules extracellulaires issues de cellules cultivées dans des conditions hypoxiques et leurs utilisations
Yu et al.	2022	Anisotropic hydrogel fabricated by controlled diffusion as a bio-scaffold for the regeneration of cartilage injury
CN105031724B (zh)	2017-10-13	一种组织工程软骨支架及其制备方法
CN104491925A (zh)	2015-04-08	一种复合骨髓间充质干细胞的凝胶支架移植系统及其应用
CN101148657A (zh)	2008-03-26	转化生长因子beta2基因修饰的组织工程化软骨的构建
Zhu et al.	2025	Sustained slow-release TGF-β3 in a three-dimensional-printed titanium microporous scaffold composite system promotes ligament-to-bone healing
Kang	2021	Biofabricated platforms for wound healing and skin regeneration
CN117531048A (zh)	2024-02-09	一种可注射软骨脱细胞基质的仿生水凝胶材料及制备方法
CN116350852A (zh)	2023-06-30	提升力学性能并多位点捕获铜离子的纤维海绵支架及制法
Tümtaş	2015	Three Dimensional Glycosaminoglycan Mimetic Peptide Amphiphile Hydrogels for Regenerative Medicine Applications
Ghanavati et al.	0	Characterization of a three-dimensional organotypic co-culture skin model for epidermal differentiation of rat adipose-derived stem cells. Cell J. 2016; 18 (3): 289-301
HK1152338B (en)	2023-03-24	Extracellular matrix compositions
HK1152338A (en)	2012-02-24	Extracellular matrix compositions

Legal Events

Date	Code	Title	Description
2004-09-21	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040917
2004-09-21	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040917
2005-08-24	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823
2005-11-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051116
2005-11-25	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051124
2006-04-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060404
2006-06-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060629
2006-07-19	TRDD	Decision of grant or rejection written
2006-07-26	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725
2006-08-31	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060824
2006-09-01	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2009-08-13	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090901 Year of fee payment: 3
2009-08-18	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20100901 Year of fee payment: 4
2010-09-01	LAPS	Cancellation because of no payment of annual fees